Literature DB >> 26654728

Lobectomy for Non-Small Cell Lung Cancer by Video-Assisted Thoracic Surgery: Effects of Cumulative Institutional Experience on Adequacy of Lymphadenectomy.

Paul C Lee1, Mohamed Kamel2, Abu Nasar2, Galal Ghaly2, Jeffrey L Port2, Subroto Paul2, Brendon M Stiles2, Weston G Andrews2, Nasser K Altorki2.   

Abstract

BACKGROUND: Because video-assisted thoracic surgery (VATS) lobectomies are increasingly being performed by thoracic surgeons, the adequacy of lymph node clearance by VATS compared with thoracotomy has been questioned, raising the possibility that patients are being understaged. One factor that may be overlooked in published studies is the learning curve of the surgeons and surgical volume in the adoption of VATS lobectomy. This study examined the effect of cumulative institutional VATS lobectomy experience on the adequacy of lymphadenectomy.
METHODS: We retrospectively reviewed a prospective database to identify 500 consecutive patients who underwent VATS lobectomy for non-small cell lung cancer (NSCLC) at our institution between 2002 and 2012. For comparative purposes, the cohort was divided into halves, with an early group (first 250 cases) vs a late group (next 250 cases). Clinical and pathologic factors were analyzed. A propensity-matching analysis controlling for age, gender, pathologic stage, and percentage of forced expiratory volume in 1 second was done to compare survival and adequacy of lymphadenectomy.
RESULTS: Patients operated on in the late group were significantly older (72 vs 69 years, p = 0.001) and had worse pulmonary functions (median forced expiratory volume in 1 second 83% vs 91%, p < 0.001; median diffusion capacity of the lung for carbon monoxide, 76% vs 85%, p < 0.001). Clinical and pathologic tumor sizes were significantly larger in the late group compared with the early group, with a median of 2.0 vs 1.8 cm (p = 0.002) for clinical T size and median of 2.1 vs 2.0 cm (p = 0.003) for pathologic T size. Patients in the late group had significantly more advanced clinical and pathologic stage distribution. The total number of lymph nodes and the number of nodal stations removed were significantly greater in the late group (p = 0.012) than in the early group (p < 0.001), and same results were obtained after propensity matching. No difference was seen in disease-free survival between the propensity-matched early vs late groups at 3 years (82% vs 85%, p = 0.187).
CONCLUSIONS: For patients with NSCLC resected by VATS lobectomy, cumulative institutional experience significantly and positively affects the adequacy of lymphadenectomy. This may be related to the initial surgeon's learning curve with VATS lobectomy. As the experience with VATS lobectomy becomes more mature, the procedure is increasingly being performed on older patients, often with more compromised pulmonary function and more advanced stage disease. Despite the expanded inclusion of older and sicker patients for VATS lobectomy, no compromise was seen in their disease-free survival.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26654728     DOI: 10.1016/j.athoracsur.2015.09.073

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

1.  The association of nodal upstaging with surgical approach and its impact on long-term survival after resection of non-small-cell lung cancer.

Authors:  Mark W Hennon; Luke H DeGraaff; Adrienne Groman; Todd L Demmy; Sai Yendamuri
Journal:  Eur J Cardiothorac Surg       Date:  2020-05-01       Impact factor: 4.191

Review 2.  Nowadays open-chest surgery in the era of fast-track management.

Authors:  Ricardo Navarro; Rodrigo Benavidez
Journal:  J Vis Surg       Date:  2017-01-05

Review 3.  Lymph node dissection during sublobar resection: why, when and how?

Authors:  Pascal-Alexandre Thomas
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 4.  Prolonged air leak following video-assisted thoracoscopic major lung resection: newer avenues to manage an age-old problem.

Authors:  Kaushalendra Rathore; Mark Newman
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-01-18

Review 5.  Current perspective on uniportal and multiportal video-assisted thoracic surgery during lobectomy for lung cancer.

Authors:  Danilo Coco; Silvana Leanza
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-10-06

6.  Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC.

Authors:  Baihua Zhang; Qin Xiao; Haifan Xiao; Jie Wu; Desong Yang; Jinming Tang; Xu Li; Zhining Wu; Yong Zhou; Wenxiang Wang
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

7.  Robotic lobectomy for lung cancer: initial experience of a single institution in Korea.

Authors:  Seha Ahn; Jin Yong Jeong; Hyung Woo Kim; Joong Hyun Ahn; Giyong Noh; Soo Seog Park
Journal:  Ann Cardiothorac Surg       Date:  2019-03

8.  National adoption of video-assisted thoracoscopic surgery (VATS) lobectomy: the Italian VATS register evaluation.

Authors:  Duilio Divisi; Luca Bertolaccini; Mirko Barone; Dario Amore; Desideria Argnani; Gino Zaccagna; Piergiorgio Solli; Gaetano Di Rienzo; Carlo Curcio; Roberto Crisci
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  What is difficult about doing video-assisted thoracic surgery (VATS)? A retrospective study comparing VATS anatomical resection and conversion to thoracotomy for lung cancer in a university-based hospital.

Authors:  Si-Wook Kim; Jong-Myeon Hong; Dohun Kim
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

10.  Video-assisted versus open thoracotomy lobectomy: comparison on lymphadenectomy and survival in early stage of lung cancer.

Authors:  Dariusz A Dziedzic; Marcin Zbytniewski; Grzegorz M Gryszko; Marcin M Cackowski; Renata Langfort; Tadeusz M Orlowski
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.